After the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase. I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an...
Teva is going to hit a major resistance line causing a bounce back making two very high-profit scenarios that can be taken advantage of. I would recommend a entry of $8.50 or higher and an exit with your own judgment and stop losses.
Amarin ready for a dive to at least $17 for institutional re-accumulation before violating thru resistance and making new highs to $30 this year. Temporary short which I will re-evaluate and flip after liquidity is taken from support areas. NASDAQ:AMRN
As Adial Pharmaceuticals advances its Phase 3 clinical trial of AD04 for the treatment of alcohol use, insiders are showing confidence in the company. Today they appointed Mark Howard Peikin as chief strategy officer, and he took the position without a salary. Instead, he accepted a stock option as his sole compensation plan. Chief medical officer Johnson A....
I've been waiting on this trend line cross in Exelixis for quite a while now. It's been getting lots of analyst upgrades, and the valuation has been looking better and better. I actually bought some of this in anticipation of the break yesterday, so I'm in the green today. Exelixis's valuation got a 99/100 score from S&P Capital IQ. It has an attractive P/E of 8....
Johnson & Johnson beat Wall Street's earnings expectations yesterday and raised its full-year guidance. The company has also been steadily settling opioid lawsuits, with another settlement rumored to be in the works soon. JNJ is rated highly undervalued by S&P Capital IQ, and its post-earnings run looks to be the slow, steady kind rather than a big spike. That's...
with new products addressing aesthetic industry should recover when volume starts to kick in
After noticing some call buying activity in Alexion Pharmaceuticals today, I gave the stock a look. Analysts like Alexion. It has an 8.8/10 analyst summary score and an average price target of about $146.50 (versus the current price of about $113). S&P Global Intelligence rates it 85/100 for quality and 87/100 for financial health. Its growth stability earns a...
Abbvie has been surging lately after a bullish trend line break, but it remains undervalued at the current price. The analyst summary score for Abbvie is 9.6/10, and the average analyst price target is $92 per share. Personally, I think Abbvie's strong earnings forecast and 5.5% dividend yield justifies $100 per share. Call volume in Abbvie is very bullish today...
Ascending Wedge Reversal. Volume is there and ready to go. Generic opioid manufacturers have been beaten down recently over fear of a copious monetary fine, but MNK has an established diverse profile. Do NOT miss this stock when it runs. Break above $4.15 and were off Long Term Target: $12.90
Pressure is building and a breakout could be imminent. It's taken 6 years from May 2013 where the high was 1816 Needs substantive news to make the push over the 1750s
Bear Trend Reversal - Long term downtrend rejected with bullish RSI divergence on the weekly. These hops off a long-term bear trend reversals can be swift and powerful. I've played these before and won (DAN...TQQQ after '18 Christmas)..but I've also played these and lost (MAXR). I've previously played these directly on the instrument, but this time I'm playing...
Cassava Sciences (SAVA) just got some positive clinical trial data on their Alzheimer’s drug. The result caused one analyst firm to upgrade SAVA’s price target from $3.00 per share to $6.00 per share. SAVA’s got a 9.4/10 analyst summary score, with most analysts rating the stock a “buy.” I entered SAVA Friday morning at $2.16 per share. It’s already up almost 100%...
Analysts have been lowering their earnings forecasts on Athenex, Inc., causing the stock to crash. However, the company not only met earnings expectations on its report this morning, but also beat sales expectations and raised its full-year revenue guidance from a 32.5% increase to a 37.5% increase year-over-year. That's a pretty big bump, and it could cause...
Nektar Therapeutics got a big upside surprise on its earnings report for both earnings and revenue. With earnings and revenue trending up, $21-22 is a fair price for the stock given analyst estimates from before the earnings report. There's resistance at 21.34, so we may initially get rejected from that level. In the near-to-mid-term, however, the earnings beat...
Still bullish on AZN.L but ascending broadening wedge : - Need to break 7 580$ resistance - RSI divergence - MM20 > MM50 Statiscally in 80% of cases, the exit of this pattern is bearish. So, I will open a short position around 7 400 $. (TPs on chart) Always 2 gap to fill : - Around 6 930 $ - Around 6 550 $ Happy trading
After years of going from top-left to bottom-right, there was a Double Bottom bounce with an Ascending Triangle currently sitting at the top of bounce. NASDAQ pre-market volume is quite nice, and the weekly volume has been consistent with price movement direction. The weekly EMA and SMA are moving from vertical to horizontal, the last three weekly candles are...
MNK is dead or almost dead. Often times there is a dead cat bounce in stocks like these, as 'everybody' gets the same idea to throw some money at it. This is a high risk scenario but with potentially good risk to reward ratios. Disclaimers : I've clearly said this is high risk. This not advice to trade in securities. I am simply showing what may happen from...